Zobrazeno 1 - 10 of 126 pro vyhledávání: '"L, Stigendal"'
1
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment
Autor: E, Berntorp, J, Astermark, F, Baghaei, D, Bergqvist, M, Holmström, B, Ljungberg, A, Norlund, J, Palmblad, P, Petrini, L, Stigendal, J, Säwe
Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 18(2)
In an ongoing health-technology assessment of haemophilia treatment in Sweden, performed by the governmental agency Dental and Pharmaceutical Benefits Agency (TLV; tandvårds-och lākemedelsförmånsverket), the Swedish Council on Health Technology A
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7b71984e02d0181198c2da75e8c9f8b9
https://pubmed.ncbi.nlm.nih.gov/22151198
Zobrazit plný text záznamu
3
[Better AVK treatment with self monitoring. Dosage can be regulated in time]
Autor: L, Stigendal, U, André, B, Christenson
Publikováno v: Lakartidningen. 96(20)
As long-term anticoagulant treatment, with warfarin for instance, is associated with a risk of both thrombotic and thrombolytic complications, blood testing for dose regulation is necessary at 3-8-week intervals, which is expensive and inconvenient f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c23a4654ad224316da268f837a457d2b
https://pubmed.ncbi.nlm.nih.gov/10380494
Zobrazit plný text záznamu
5
Major surgery seems not to influence HIV disease progression in haemophilia patients
Autor: J, Astermark, T, Löfqvist, S, Schulman, L, Stigendal, S, Lethagen, I M, Nilsson, E, Berntorp
Publikováno v: British journal of haematology. 103(1)
The influence of major surgery on HIV disease progression and decline in CD4+ cell count was evaluated in 23 seropositive haemophilia patients. 24 HIV-infected patients served as non-operated controls. In addition, 32 age-matched seronegative subject
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d569f06bd1d0332257b2efbc309c90e0
https://pubmed.ncbi.nlm.nih.gov/9792282
Zobrazit plný text záznamu
6
[Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates]
Autor: J, Astermark, E, Berntorp, L, Stigendal, H, Johnsson
Publikováno v: Lakartidningen. 95(1-2)
HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d5f68df48cec102b877e1e6075e83168
https://pubmed.ncbi.nlm.nih.gov/9458646
Zobrazit plný text záznamu
9
Treatment with a pure factor IX concentrate in a patient with moderate hemophilia B undergoing bilateral total hip replacement
Autor: L. Stigendal, L. Tengborn, C. Stromberg, G. Gustafsson, P. Hultmark
Publikováno v: Transfusion. 33(11)
Recently, a pure factor IX concentrate, licensed in Sweden as Immunine, was prepared through ion exchange and hydrophobic chromotography. Virus inactivation included two steps of steam treatment. Reconstituted Immunine could be kept at room temperatu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3bdbd89485f9f78f6aa2ba315b343f6
https://pubmed.ncbi.nlm.nih.gov/8259599
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje